DRMA
Dermata Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.49 / 10
Outperform
Analyst coverage is limited but highly positive, with a single Strong Buy recommendation. Fund‑flow scores are solid (7.48), driven by inflows in small and medium investors, though overall trend is negative and the stock price fell 1.67%.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-08-21
InstitutionMaxim Group
Times predicted2
Historical Win Rate50.0%
Is money flowing into or out of DRMA?
- DRMA holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.49/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
